These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1854181)

  • 1. Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam.
    van Ogtrop ML; Guiot HF; Mattie H; van Strijen E; Sekh BR; van Furth R
    Antimicrob Agents Chemother; 1991 May; 35(5):983-5. PubMed ID: 1854181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigemonam, an oral monobactam.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1988 Jan; 32(1):84-91. PubMed ID: 3279906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in-vitro activity of tigemonam, a new monobactam.
    Rylander M; Gezelius L; Norrby SR
    J Antimicrob Chemother; 1988 Sep; 22(3):307-13. PubMed ID: 3182428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of tigemonam against multiresistant nosocomial Enterobacteriaceae.
    Giamarellou H; Pephanis A; Grammatikou M; Avlamis A; Papoulias G
    J Chemother; 1989 May; 1 Suppl 2():32-5. PubMed ID: 2809700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of aztreonam on the fecal aerobic flora in children].
    Borderon JC; Rastegar A; Ramponi N; Gold F; Laugier J
    Pathol Biol (Paris); 1987 May; 35(5):665-8. PubMed ID: 3112714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective decontamination of intestinal flora with oral aztreonam in compromised children].
    Sakata H; Kakehashi H; Fujita K; Yoshioka H
    Kansenshogaku Zasshi; 1989 Oct; 63(10):1165-70. PubMed ID: 2614090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.
    van Ogtrop ML; Guiot HF; Mattie H; van Furth R
    Antimicrob Agents Chemother; 1991 May; 35(5):976-82. PubMed ID: 1854180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antimicrobial activity of tigemonam, a new orally administered monobactam.
    Fuchs PC; Jones RN; Barry AL
    Antimicrob Agents Chemother; 1988 Mar; 32(3):346-9. PubMed ID: 3259122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of antibiotics and intestinal flora associated endotoxin in mice.
    Goris H; de Boer F; van der Waaij D
    Scand J Infect Dis; 1986; 18(1):55-63. PubMed ID: 3008311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of the monobactams.
    Sykes RB; Bonner DP
    Rev Infect Dis; 1985; 7 Suppl 4():S579-93. PubMed ID: 3909315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of tigemonam dicholate (SQ 30836) and interaction with beta-lactamases of gram-negative bacteria.
    Raimondi A; Cocuzza CE
    J Chemother; 1989 May; 1 Suppl 2():13-21. PubMed ID: 2809698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of tigemonam, an oral monobactam, against gram-negative rods, including variants in beta-lactamase-production.
    Brown J; Yang YJ; Livermore DM
    J Antimicrob Chemother; 1989 Feb; 23(2):201-7. PubMed ID: 2785102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of broad-spectrum parenteral antibiotics on "colonization resistance" of intestinal microflora of humans.
    Barza M; Giuliano M; Jacobus NV; Gorbach SL
    Antimicrob Agents Chemother; 1987 May; 31(5):723-7. PubMed ID: 3496848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious interpretive error among three commercial systems for susceptibility testing of aztreonam. Aztreonam Study Group.
    Marshall SA
    Diagn Microbiol Infect Dis; 1995 Jul; 22(3):249-51. PubMed ID: 8565412
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation of aztreonam susceptibility results obtained with the MicroScan system to reference tests.
    Zimmer BL; Brattebo J; Bryant M; Capo A; Chipman A; Miller R; Wehr C; Van Pelt L
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):111-20. PubMed ID: 9368088
    [No Abstract]   [Full Text] [Related]  

  • 17. The in-vitro activity of SQ 82,291, a new monobactam, in comparison with aztreonam.
    García-Rodríguez JA; García-Sánchez JE; Plata A; Trujillano I
    J Antimicrob Chemother; 1986 Mar; 17(3):303-7. PubMed ID: 3754552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of aztreonam and tigemonam against Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.
    van Ogtrop ML; Mattie H; Guiot HF; van Strijen E; Sekh BR; van Furth R
    Antimicrob Agents Chemother; 1991 Mar; 35(3):417-22. PubMed ID: 2039191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth curve patterns of Escherichia coli, Serratia marcescens, and Proteus vulgaris submitted to different tigemonam concentrations.
    Yourassowsky E; van der Linden MP; Lismont MJ; Crokaert F
    J Chemother; 1989 May; 1 Suppl 2():49-53. PubMed ID: 2681561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.